Ascelia Pharma AB (SE:ACE)
:ACE
Top Page
Ascelia Pharma AB
(ACE)
Select Model
Select Model
Rating:44Neutral
Price Target:
kr3.00
▼(-5.36% Downside)
Action:ReiteratedDate:02/09/26
The score is primarily held down by weak financial performance (pre-revenue, persistent losses and cash burn, and declining equity), despite improvements in losses/burn and low leverage. Technicals also lean bearish with the stock trading below major moving averages. Valuation remains challenged due to negative earnings and no dividend support.
Positive Factors
Orphan-drug niche focus
Ascelia's focus on orphan oncology indications and a lead program addressing imaging for patients with impaired kidney function positions it in a high-unmet-need niche. Orphan programs often benefit from regulatory incentives, concentrated patient populations and clearer commercial pathways versus broad indications.
Negative Factors
Pre-revenue profile
The company has no reported revenue, meaning commercial validation and recurring cash inflows are absent. Long dependence on clinical and regulatory milestones makes sustained operations contingent on successful trials or external funding rather than organic cash generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Orphan-drug niche focus
Ascelia's focus on orphan oncology indications and a lead program addressing imaging for patients with impaired kidney function positions it in a high-unmet-need niche. Orphan programs often benefit from regulatory incentives, concentrated patient populations and clearer commercial pathways versus broad indications.
Read all positive factors
Ascelia Pharma AB (ACE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr367.29M
Dividend YieldN/A
Average Volume (3M)1.75M
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue GrowthN/A
EPS Growth31.62%
CountrySE
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.13
Shares Outstanding126,868,800
10 Day Avg. Volume1,883,755
30 Day Avg. Volume1,753,338
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)3.67
Price to Sales (P/S)0.00
P/FCF Ratio-5.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.28
Revenue Forecast (FY)kr63.59M
Ascelia Pharma AB Business Overview & Revenue Model
Company Description
Ascelia Pharma AB (publ), a biotech company, operates as an oncology-focused orphan drug development company in Sweden. It is developing Mangoral, a novel non-gadolinium contrast agent, which is in Phase 3 for use in MRI-scans of the liver; and On...
How the Company Makes Money
Ascelia Pharma AB generates revenue primarily through the research and development of its proprietary drug candidates. The company aims to monetize its products by progressing them through clinical trials and eventually bringing them to the market...
Ascelia Pharma AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
62
Positive
Cash Flow
25
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -938.00K | -1.05M | -3.89M | -8.72M |
| EBITDA | -71.21M | -67.69M | -108.56M | -132.06M | -128.42M |
| Net Income | -76.25M | -80.03M | -109.29M | -131.22M | -125.90M |
Balance Sheet | |||||
| Total Assets | 111.94M | 140.92M | 87.07M | 218.57M | 333.49M |
| Cash, Cash Equivalents and Short-Term Investments | 49.86M | 75.26M | 21.86M | 149.56M | 261.60M |
| Total Debt | 1.04M | 25.40M | 1.06M | 484.00K | 1.66M |
| Total Liabilities | 12.47M | 61.98M | 12.74M | 37.71M | 25.66M |
| Stockholders Equity | 99.47M | 78.94M | 74.33M | 180.86M | 307.83M |
Cash Flow | |||||
| Free Cash Flow | -72.31M | -62.84M | -126.79M | -125.33M | -116.60M |
| Operating Cash Flow | -72.25M | -62.84M | -126.79M | -125.26M | -116.56M |
| Investing Cash Flow | -57.00K | 0.00 | 46.00K | -65.00K | -38.00K |
| Financing Cash Flow | 48.21M | 115.19M | -936.00K | -1.10K | 184.87M |
Ascelia Pharma AB Technical Analysis
Negative
3.17
Price Trends
2.94
Negative
2.96
Negative
3.50
Negative
Market Momentum
-0.03
Positive
47.41
Neutral
56.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACE, the sentiment is Negative. The current price of 3.17 is above the 20-day moving average (MA) of 2.95, above the 50-day MA of 2.94, and below the 200-day MA of 3.50, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 47.41 is Neutral, neither overbought nor oversold. The STOCH value of 56.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ACE.
Ascelia Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | kr992.95M | 7.07 | 81.19% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr182.72M | -2.92 | -51.35% | ― | ― | -34.02% | |
46 Neutral | kr145.06M | 121.99 | -16.90% | ― | 4.64% | ― | |
45 Neutral | kr286.58M | -1.89 | -16.51% | ― | ― | 31.37% | |
44 Neutral | kr367.29M | -4.79 | -79.60% | ― | ― | 31.62% | |
42 Neutral | kr26.30M | -0.24 | -186.13% | ― | ― | 0.30% |
* Healthcare Sector Average
SE:ACE
Ascelia Pharma AB
2.90
0.39
15.34%
SE:XBRANE
Xbrane Biopharma AB
7.04
-15.84
-69.22%
SE:ISOFOL
Isofol Medical AB
0.65
-0.93
-58.89%
SE:GUARD
Guard Therapeutics International AB
1.30
-10.60
-89.04%
SE:IMMU
Immunicum AB
4.68
-0.39
-7.69%
SE:CANTA
Cantargia AB
3.99
2.69
207.23%
Ascelia Pharma AB Corporate Events
Ascelia Pharma’s Orviglance NDA Accepted by FDA as Cash Runway Extends Beyond 2026 Decision
Feb 5, 2026
Ascelia Pharma reported that the US Food and Drug Administration has formally accepted its New Drug Application for Orviglance, setting a PDUFA decision date of 3 July 2026 and confirming the completeness of a development package that includes nin...
Ascelia Pharma Deputy CEO and CFO Julie Waras Brogren to Depart for New CEO Role
Jan 21, 2026
Ascelia Pharma has announced that Deputy CEO and CFO Julie Waras Brogren will leave the company to assume a CEO role elsewhere, after playing a key role in advancing the commercial strategy, partnering efforts and financial function, particularly ...
Ascelia Pharma Appoints Nomination Committee Ahead of 2026 AGM
Dec 22, 2025
Ascelia Pharma has appointed its Nomination Committee for the Annual General Meeting to be held in Malmö on 4 May 2026, in line with its governance rules that require representatives from the three largest shareholders together with the chair...
Ascelia Pharma Adjusts Share Structure Following Share Saving Program
Nov 28, 2025
Ascelia Pharma AB announced a change in its share structure due to the conversion of 53,335 series C shares into ordinary shares as part of a performance-based share saving program. This adjustment results in a total of 127,902,580 shares, impacti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.